EMA Authorised: Opzelura (ruxolitinib phosphate) — Incyte Biosciences Distribution B.V.

View source ↗

Summary

EMA has authorised Opzelura (ruxolitinib phosphate) for the treatment of vitiligo in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• Opzelura (ruxolitinib)

Snippet

Status: Authorised. Therapeutic area: Vitiligo. MAH: Incyte Biosciences Distribution B.V.. Decision date: 19/06/2026